Brewer M, Angioli R, Scambia G, et al. - Whether improved progression free survival (PFS) and overall survival (OS) can be achieved with schedule dependent chemo-immunotherapy with oregovomab in patients with optimally resected, Stage III/IV ovarian cancer, was investigated in this randomized phase II study. Participants were recruited from both academic centers and private practice in the US and Italy. Randomization of the patients to receive standard six cycle IV carboplatin-paclitaxel chemotherapy (CP) vs CP plus four immunizations with oregovomab (CPO), was done. A median follow up of 42 months was performed. Findings revealed that a front line chemo-immunotherapy treatment resulted in increases in PFS and OS in ovarian cancer patients. These increases were of statistically and clinically significant magnitude. In this study, the earlier noted possible clinical benefit of IV CP when given with oregovomab was further refined.